EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study

Niklas Worm Andersson iD, Emilia Myrup Thiesson, Ulrike Baum, Nicklas Pihlström, Jostein Starrfelt, Kristýna Faksová, Eero Poukka, Hinta Meijerink, Rickard Ljung, Anders Hviid

BMJ · 2023

DOI: 10.1136/bmj-2022-075286 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift BMJ, 2023. Verfasst von Niklas Worm Andersson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark nian@ssi.dk. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To estimate the effectiveness of the bivalent mRNA booster vaccines containing the original SARS-CoV-2 and omicron BA.4-5 or BA.1 subvariants as the fourth dose against severe covid-19.

Design

Nationwide cohort analyses, using target trial emulation.

Setting

Denmark, Finland, Norway, and Sweden, from 1 July 2022 to 10 April 2023.

Participants

People aged ≥50 years who had received at least three doses of covid-19 vaccine (that is, a primary course and a first booster). Main outcome measures The Kaplan-Meier estimator was used to compare the risk of hospital admission and death related to covid-19 in people who received a bivalent Comirnaty (Pfizer-BioNTech) or Spikevax (Moderna) BA.4-5 or BA.1 mRNA booster vaccine as a fourth dose (second booster) with three dose (first booster) vaccinated people and between four dose vaccinated people.

Results

A total of 1 634 199 people receiving bivalent BA.4-5 fourth dose booster and 1 042 124 receiving bivalent BA.1 fourth dose booster across the four Nordic countries were included. Receipt of a bivalent BA.4-5 booster as a fourth dose was associated with a comparative vaccine effectiveness against admission to hospital with covid-19 of 67.8% (95% confidence interval 63.1% to 72.5%) and a risk difference of –91.9 (95% confidence interval –152.4 to –31.4) per 100 000 people at three months of follow-up compared with having received three doses of vaccine (289 v 893 events). The corresponding comparative vaccine effectiveness and risk difference for bivalent BA.1 boosters (332 v 977 events) were 65.8% (59.1% to 72.4%) and –112.9 (–179.6 to –46.2) per 100 000, respectively. Comparative vaccine effectiveness and risk difference against covid-19 related death were 69.8% (52.8% to 86.8%) and –34.1 (–40.1 to –28.2) per 100 000 for bivalent BA.4-5 booster (93 v 325 events) and 70.0% (50.3% to 89.7%) and –38.7 (–65.4 to –12.0) per 100 000 for BA.1 booster (86 v 286) as a fourth dose. Comparing bivalent BA.4-5 and BA.1 boosters as a fourth dose directly resulted in a three month comparative vaccine effectiveness and corresponding risk difference of –14.9% (–62.3% to 32.4%) and 10.0 (–14.4 to 34.4) per 100 000 people for admission to hospital with covid-19 (802 v 932 unweighted events) and –40.7% (–123.4% to 42.1%) and 8.1 (–3.3 to 19.4) per 100 000 for covid-19 related death (229 v 243 unweighted events). The comparative vaccine effectiveness did not differ across sex and age (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19COVID-19 VaccinesHumansCohort StudiesRNA, MessengerSARS-CoV-2Scandinavian and Nordic CountriesMiddle Aged

Substanzen

COVID-19 VaccinesRNA, Messenger

Autor:innen und Institutionen

  • Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark nian@ssi.dk.
  • Department of Epidemiology Research, Statens Serum Institut, Copenhagen, Denmark.
  • Infectious Disease Control and Vaccinations Unit, Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland.
  • Division of Licensing, Swedish Medical Products Agency, Uppsala, Sweden.
  • Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Oslo, Norway.
  • Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

ORCID-Profile: Niklas Worm Andersson

Zitieren

APA

Andersson, N. W., Thiesson, E. M., Baum, U., Pihlström, N., Starrfelt, J., Faksová, K., Poukka, E., Meijerink, H., Ljung, R., & Hviid, A. (2023). Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study. BMJ. https://doi.org/10.1136/bmj-2022-075286

Vancouver

Andersson NW, Thiesson EM, Baum U, Pihlström N, Starrfelt J, Faksová K, et al. Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study. BMJ. 2023. doi:10.1136/bmj-2022-075286

BibTeX
@article{Andersson2023,
  author = {Andersson, Niklas Worm and Thiesson, Emilia Myrup and Baum, Ulrike and Pihlström, Nicklas and Starrfelt, Jostein and Faksová, Kristýna and Poukka, Eero and Meijerink, Hinta and Ljung, Rickard and Hviid, Anders},
  title = {Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study},
  journal = {BMJ},
  year = {2023},
  doi = {10.1136/bmj-2022-075286}
}
Kostenlos starten →